Larotrectinib Sulfate Patent Expiration
Larotrectinib Sulfate is Used for treating various solid tumors in pediatric patients exhibiting an NTRK gene fusion. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Larotrectinib Sulfate Patents
Given below is the list of patents protecting Larotrectinib Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vitrakvi | US10045991 | Methods of treating pediatric cancers | Apr 04, 2037 | Bayer Healthcare |
| Vitrakvi | US10137127 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | Apr 04, 2037 | Bayer Healthcare |
| Vitrakvi | US10668072 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | Apr 04, 2037 | Bayer Healthcare |
| Vitrakvi | US11191766 | Methods of treating pediatric cancers | Apr 04, 2037 | Bayer Healthcare |
| Vitrakvi | US11484535 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | Apr 04, 2037 | Bayer Healthcare |
| Vitrakvi | US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Aug 15, 2036 | Bayer Healthcare |
| Vitrakvi | US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Aug 15, 2036 | Bayer Hlthcare |
| Vitrakvi | US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Healthcare |
| Vitrakvi | US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Hlthcare |
| Vitrakvi | US10285993 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Hlthcare |
| Vitrakvi | US10813936 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Hlthcare |
| Vitrakvi | US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Healthcare |
| Vitrakvi | US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Nov 16, 2035 | Bayer Hlthcare |
| Vitrakvi | US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Dec 23, 2029 | Bayer Healthcare |
| Vitrakvi | US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Dec 23, 2029 | Bayer Hlthcare |
| Vitrakvi | US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
| Vitrakvi | US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Oct 21, 2029 | Bayer Healthcare |
| Vitrakvi | US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Oct 21, 2029 | Bayer Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Larotrectinib Sulfate's patents.
Latest Legal Activities on Larotrectinib Sulfate's Patents
Given below is the list recent legal activities going on the following patents of Larotrectinib Sulfate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2024 | US10813936 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799505 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9447104 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Feb, 2024 | US10774085 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2023 | US10668072 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9127013 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Nov, 2022 | US10285993 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Nov, 2022 | US11484535 |
| Recordation of Patent Grant Mailed Critical | 01 Nov, 2022 | US11484535 |
| Sequence Moved to Public Database | 01 Nov, 2022 | US11484535 |
Larotrectinib Sulfate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List